CoronaVac vaccine reduces mortality by 97%, Pfizer by 80%

The Chinese vaccine against the coronavirus CoronaVac reduces the mortality of this disease by 97%, while the American Pfizer does it by 80%, according to the preliminary results of a study published and carried out among the Uruguayan population.

“The reduction in mortality due to Covid-19, having elapsed more than 14 days since the last dose of the vaccine, is 97% for Coronavac and 80% for Pfizer”, indicates the study of the effectiveness of vaccination against SARS-CoV-2 in Uruguay in 2021 ”, carried out by the Ministry of Public Health (MSP), the AFP news agency reported.

The report says that of the total number of people fully immunized with CoronaVac as of May 25 (712,716), 5,360 have tested positive for the coronavirus. Of these, 19 had to be hospitalized in an intensive care unit and 6 died.

Meanwhile, of the total of people fully immunized with Pfizer on the same date (149,329), 691 were infected with Covid, only one had to be admitted to CTI and 8 died. The report states that, in this case, they were all over 80 years old.

As a percentage, the reduction in cases with the Sinovac laboratory vaccine is 57%, and with Pfizer it is 75%.

Meanwhile, in intensive care unit hospitalizations, the report noted an efficacy of 95% for CoronaVac and 99% for Pfizer.

The study specifies that the figures are preliminary and “should be interpreted with caution, as they do not take into account the age of people, their co-morbidities and groups with high exposure”, such as health workers, added the AFP.

These statistical adjustments will be communicated in the next reports, the study abounded.

Uruguay, once an example in the management of the pandemic, with 3.5 million inhabitants, who have never resorted to confinement and keeps much of its activities open, is going through the worst moment of health.

The government of President Luis Lacalle Pou is betting everything on vaccination, which has made significant progress since its launch on March 1, AFP said.

Currently, 47% of the Uruguayan population has already received the first dose of vaccine and 28% the second.